Evidence-Based Supplements for Cholesterol Management: A Clinical Review of Randomized Trials and Meta-Analyses
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine & Integrative/Holistic Medicine
Osher Fellow, Andrew Weil Center for Integrative Medicine | IFM Scholar
Updated April 2026
Introduction
Dyslipidemia remains one of the most important modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD). While statin therapy has transformed cardiovascular prevention, up to 10% of patients experience side effects that reduce adherence, and many patients with low-to-moderate ASCVD risk may not yet qualify for pharmacotherapy. In this space, nutraceuticals and dietary supplements offer a legitimate, evidence-based adjunct—or, in select primary-prevention patients, a reasonable initial approach.
This article reviews the clinical trial evidence for the most effective cholesterol-lowering supplements, drawing from randomized controlled trials (RCTs), systematic reviews, and meta-analyses indexed in PubMed. Each agent is evaluated for its magnitude of LDL-C reduction, quality of evidence, mechanism of action, and safety profile. A 2022 network meta-analysis of 131 trials enrolling 13,062 participants, published in Pharmacological Research, provides an important comparative framework: it found that all analyzed nutraceuticals except policosanols were effective in lowering LDL-C, with bergamot and red yeast rice ranking highest.
The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) 2019 guidelines explicitly acknowledge the role of specific nutraceuticals—particularly plant sterols and red yeast rice—as adjuncts to lifestyle modification. The International Lipid Expert Panel (ILEP) has published position papers supporting their use in statin-intolerant patients and as complementary therapy in those not achieving LDL-C targets.
Summary Table: Evidence-Based Cholesterol-Lowering Supplements
1. Red Yeast Rice (RYR)
Evidence Level: Strong. Red yeast rice is the most extensively studied cholesterol-lowering nutraceutical. Its active compound, monacolin K, is chemically identical to lovastatin, a prescription HMG-CoA reductase inhibitor.
Key Trial Data
A 2024 systematic review and meta-analysis of 14 double-blinded clinical trials, published in Nutrients, found that RYR extract consumption reduced total cholesterol by a mean of 37.43 mg/dL and LDL-C by a mean of 35.82 mg/dL, with percentage reductions ranging from 14.3% to 22.17% across studies. A 2021 meta-analysis of 15 high-quality RCTs (1,012 participants), published in Frontiers in Pharmacology, found that compared to statins, RYR was more effective in lowering triglycerides, comparable in lowering LDL-C and raising HDL-C, and slightly less effective in lowering total cholesterol.
The most authoritative synthesis comes from a JACC Focus Seminar review, which reported that across 20 trials and 6,663 subjects, RYR reduced LDL-C by an average of 39.4 mg/dL—comparable to low-intensity statins such as pravastatin 40 mg or simvastatin 10 mg. Daily consumption was shown to reduce LDL-C by 15–25% within 6–8 weeks.
A landmark RCT by Becker et al. (2009, Annals of Internal Medicine) specifically addressed statin-intolerant patients: 62 patients with statin-associated myalgias were randomized to RYR 1,800 mg or placebo twice daily for 24 weeks alongside therapeutic lifestyle change. RYR significantly decreased LDL cholesterol without increasing CPK or muscle pain.
Combination Data
The RYR-berberine combination (3 mg monacolin K + 500 mg berberine) has been evaluated in a meta-analysis of 14 RCTs with 3,159 subjects, showing a mean LDL-C reduction of 23.6 mg/dL (14.7%) with concomitant improvements in HDL-C, triglycerides, and glucose. The RYR-phytosterol combination achieved an LDL-C reduction of 27% and apoB decrease of 19% in a double-blind, placebo-controlled RCT of 90 hypercholesterolemic subjects.
Safety Considerations
Because monacolin K is pharmacologically identical to lovastatin, RYR carries the same theoretical risks: hepatotoxicity, myopathy, and drug interactions. However, meta-analytic data show no increase in life-threatening side effects compared to placebo. The major practical concern is product quality variability—commercial preparations vary widely in monacolin K content, and citrinin contamination has been documented. Clinicians should recommend third-party-verified products and monitor liver enzymes and CK periodically.
2. Berberine
Evidence Level: Moderate to Strong. Berberine is an isoquinoline alkaloid derived from several plants (Berberis, goldenseal, Oregon grape). Its mechanism of action is distinct from statins: berberine acts as a natural PCSK9 inhibitor and upregulates hepatic LDL receptors, while also activating AMPK to improve insulin sensitivity and glucose metabolism.
Key Trial Data
A 2023 meta-analysis of 41 RCTs with 4,838 patients, published in Nutrients, found berberine-containing products significantly reduced total cholesterol by 17.42 mg/dL, LDL by 14.98 mg/dL, and triglycerides by 18.67 mg/dL while raising HDL by 1.97 mg/dL. A 2025 Frontiers in Pharmacology meta-analysis of 12 placebo-controlled RCTs (889 patients) confirmed significant reductions in LDL-C, TC, fasting glucose, triglycerides, and waist circumference, with an interesting finding that short-term intervention (90 days or less) was more effective for LDL-C than longer treatment.
An umbrella review synthesizing 13 meta-analyses with over 17,000 total participants concluded that berberine supplementation was effective in reducing LDL-C, TC, and TG while increasing HDL-C, and recommended berberine as an adjuvant anti-hyperlipidemic agent.
Limitations
Trial quality is a significant concern: the 2018 Cochrane-style meta-analysis of 16 RCTs (2,147 participants) noted that most trials had low methodological quality in randomization, allocation concealment, and blinding. Most evidence comes from Chinese populations, which limits generalizability. Gastrointestinal side effects (diarrhea, constipation, nausea) occur in some patients at standard doses.
3. Bergamot Polyphenolic Fraction
Evidence Level: Moderate, Growing. Bergamot (Citrus bergamia) contains unique flavonoids—brutieridin and melitidin—that share structural features with HMG-CoA reductase substrates and demonstrate statin-like activity in preclinical models. Bergamot ranked alongside RYR as the most effective nutraceutical in the 2022 network meta-analysis.
Key Trial Data
A 2023 double-blind, three-arm, placebo-controlled RCT of 90 subjects tested a standardized bergamot phytocomplex at two doses for 12 weeks. The high-dose group (700 mg/day) experienced reductions in total cholesterol of 13.2%, LDL-C of 17.7%, triglycerides of 16.6%, HOMA-IR of 12.2%, and hs-CRP of 17.9% versus both baseline and placebo, with effects visible as early as 6 weeks. An earlier trial demonstrated that 1,000 mg/day of bergamot-derived polyphenolic fraction produced LDL-C lowering similar to rosuvastatin 10 mg (approximately 40% reduction), and when combined with rosuvastatin, the effect was enhanced to 52%.
A 2024 randomized, double-blind, placebo-controlled clinical trial confirmed that a standardized bergamot extract containing 150 mg of flavonoids per day was effective in reducing TC and LDL-C in both the short and long term, starting from the second month of intake.
Caveats
Most bergamot trials have relatively small sample sizes, and results on triglycerides and HDL-C have been inconsistent across studies, likely due to variability in extraction and standardization methods. A rigorous 2025 RCT testing a combination of plant sterols, bergamot, artichoke, and hydroxytyrosol did not improve LDL-C in adults with mild hypercholesterolemia, highlighting that combining agents does not always produce additive effects—and may interfere with individual mechanisms.
4. Plant Sterols and Stanols
Evidence Level: Strong (Guideline-Endorsed). Plant sterols and stanols are the most widely guideline-endorsed nutraceutical class, with formal health claims approved by the FDA, EFSA, and recommendations from the ESC/EAS, ACC/AHA, and the National Heart Foundation of Australia. They work by competing with dietary and biliary cholesterol for intestinal absorption.
Key Trial Data
A meta-analysis of 41 trials found that intake of 2 g/day of stanols or sterols reduced LDL by approximately 10%. A meta-analysis of 124 randomized placebo-controlled trials including 9,600 adults confirmed a consistent dose-response relationship for LDL-C lowering by 6–12% with intakes of 0.6–3.3 g/day. The effects are additive with both diet and pharmacotherapy: combining plant sterols/stanols with a low-saturated-fat diet can reduce LDL by 20%, and adding them to statin therapy is more effective than doubling the statin dose. A 2024 meta-analysis of 28 RCTs (1,777 participants) confirmed significant reductions in TC, LDL-C, and apolipoprotein B.
Safety Considerations
While the cholesterol-lowering effect is well-established, recent genetic studies (Mendelian randomization data) have linked elevated circulating plant sterol concentrations with increased CVD presence, raising theoretical safety concerns. The clinical consensus is that the small increase in plasma phytosterols from supplementation at 2 g/day is likely more than offset by the LDL-C reduction, but this remains an area of active research. Beta-carotene absorption may be modestly reduced; co-supplementation can be considered.
5. Psyllium (Soluble Viscous Fiber)
Evidence Level: Strong. Psyllium (Plantago ovata) is a gel-forming viscous soluble fiber with an FDA-authorized health claim for coronary heart disease risk reduction. It increases fecal bile acid excretion, diverting hepatic cholesterol to bile acid production, and may also reduce cholesterol absorption and inhibit hepatic synthesis via short-chain fatty acid byproducts of fermentation.
Key Trial Data
A systematic review of 28 RCTs (1,924 participants) published in the American Journal of Clinical Nutrition found that a median dose of approximately 10.2 g psyllium significantly reduced LDL cholesterol by 0.33 mmol/L (approximately 12.8 mg/dL), non-HDL cholesterol by 0.39 mmol/L, and apolipoprotein B by 0.05 g/L. A classic meta-analysis of 8 controlled trials with 656 subjects showed that 10.2 g/day of psyllium adjunctive to a low-fat diet decreased LDL cholesterol an additional 5–9% beyond diet alone. A comprehensive 2023 dose-response meta-analysis (181 studies, 14,505 participants) of all soluble fibers found that LDL cholesterol was reduced by approximately 8.28 mg/dL, with the maximal dose-response at about 10 g/day.
Clinically, the value of psyllium is its additivity: when stacked on top of statin therapy, it provides meaningful further LDL lowering with an excellent safety profile and essentially no drug interactions.
6. Omega-3 Fatty Acids (EPA/DHA)
Evidence Level: Strong for Triglycerides; Nuanced for LDL-C. Omega-3 fatty acids are primarily triglyceride-lowering agents, not LDL-lowering agents. The EPA vs. DHA distinction matters significantly in clinical practice.
Key Trial Data
Meta-analyses confirm that 3–4 g/day of EPA + DHA can reduce triglycerides by 20–50% in individuals with serum TG exceeding 150 mg/dL. However, the overall effect on LDL-C is not significant. Critically, EPA can lower triglycerides without raising LDL-C, whereas DHA has been shown to modestly increase LDL-C in patients with elevated triglycerides—making pure EPA the preferred formulation for patients on statins with residual hypertriglyceridemia.
The REDUCE-IT trial (icosapent ethyl 4 g/day) demonstrated a 25% reduction in major adverse cardiovascular events in statin-treated patients with elevated triglycerides—the strongest cardiovascular outcomes data for any agent in this category. The EVAPORATE trial showed that the same dose reduced low-attenuation coronary plaque volume by 17%. However, the STRENGTH trial (EPA + DHA combination) was terminated early for futility, reinforcing the superiority of EPA monotherapy for cardiovascular outcomes.
7. Second-Tier Agents
Artichoke Leaf Extract
A meta-analysis of 9 RCTs (702 subjects) found that artichoke extract supplementation significantly reduced total cholesterol by 17.6 mg/dL, LDL-C by 14.9 mg/dL, and triglycerides by 9.2 mg/dL. An updated 2021 meta-analysis of 14 studies confirmed these findings. The mechanism involves enhanced bile acid excretion and possible inhibition of HMG-CoA reductase via cynarin and luteolin. Artichoke may be most useful as a combination partner, particularly with bergamot: a double-blind, placebo-controlled RCT of 90 subjects showed that a bergamot-artichoke combination significantly decreased triglycerides, apoB-100, TC, LDL-C, non-HDL-C, and hs-CRP versus both baseline and placebo.
Green Tea Catechins (EGCG)
Meta-analyses of 20+ RCTs show that green tea catechins (145–3,000 mg/day) produce modest reductions in total cholesterol (5–8 mg/dL) and LDL-C (2–7 mg/dL) without significant effects on HDL-C or triglycerides. A large 12-month RCT in postmenopausal women found that 1,315 mg green tea catechins per day (843 mg EGCG) significantly reduced TC, LDL-C, and non-HDL-C, with the greatest effects seen in those with elevated baseline cholesterol (8.3% TC reduction, 12.2% LDL-C reduction). The COMT genotype may influence individual response. Green tea catechins are reasonable as part of a comprehensive dietary approach but are not potent enough as standalone lipid-lowering therapy.
Garlic Extract
Meta-analyses of garlic supplementation show modest cholesterol reductions—typically around 5–10% in LDL-C (roughly 8–9 mg/dL) over 1–3 months. The mechanism involves organosulfur compounds (allicin) interfering with hepatic cholesterol synthesis. While garlic may offer mild additive benefit alongside other interventions, the effect size is too small for it to serve as a primary lipid-lowering strategy.
What Does NOT Work: Policosanols
The 2022 network meta-analysis found that policosanols—long-chain alcohols derived from sugar cane wax, once heavily marketed as cholesterol-lowering agents—had no significant effect on LDL-C, total cholesterol, HDL-C, or triglycerides versus placebo. Earlier positive trials were predominantly from a single Cuban research group; independent replication has consistently failed. Policosanols should not be recommended for lipid management.
8. Niacin (Vitamin B3): A Cautionary Story
Niacin deserves discussion because it was historically the most potent HDL-raising agent available. At doses of 1–2 g/day, niacin can increase HDL-C by 20–25%, decrease LDL-C by 12–20%, and lower triglycerides by 15–33%. The Coronary Drug Project (1960s–70s) showed reduced MI and mortality with niacin monotherapy.
However, two large modern trials—AIM-HIGH (3,414 patients) and HPS2-THRIVE (25,673 patients)—showed no incremental cardiovascular benefit when niacin was added to intensive statin therapy, despite favorable lipid changes. HPS2-THRIVE also documented excess adverse effects including myopathy, diabetes exacerbation, GI symptoms, and infections. HDL proteomics research has revealed that niacin increases HDL-associated serum amyloid A, an acute-phase protein linked to HDL dysfunction—a potential explanation for the disconnect between lipid improvements and clinical outcomes.
The lesson: niacin modifies lipid numbers impressively but does not produce the expected cardiovascular benefit in the statin era. It may retain a limited role in statin-intolerant patients who cannot achieve LDL-C goals, but it is no longer a first-line lipid-modifying strategy.
9. Clinical Integration: A Layered Approach
For a primary-prevention patient with an LDL-C of 160–180 mg/dL, low 10-year ASCVD risk, and a preference for non-pharmacological intervention, an evidence-based layered nutraceutical protocol might include:
Foundation: Mediterranean or Portfolio dietary pattern (targeting 10–20% LDL-C reduction through nutrition alone)
Tier 1 (strongest evidence for LDL-C): Red yeast rice (standardized to 10 mg monacolin K) plus plant sterols (2 g/day) plus psyllium (10 g/day)
Tier 2 (additional benefit, unique mechanisms): Berberine (500 mg BID) for its PCSK9-modulating and insulin-sensitizing effects; bergamot BPF (500–1,000 mg/day) for additional HMG-CoA inhibition and anti-inflammatory properties
For elevated triglycerides: EPA-dominant omega-3 (2–4 g/day pure EPA preferred over EPA/DHA combinations)
This layered approach, combined with structured exercise, weight optimization, and sleep/stress management, could plausibly achieve 30–40% total LDL-C reduction—overlapping with moderate-intensity statin territory. Advanced risk stratification (apoB, Lp(a), hs-CRP, coronary artery calcium scoring) should guide the intensity of intervention, and pharmaceutical escalation should remain available for patients with high absolute risk or inadequate response.
Laboratory monitoring should include baseline and follow-up lipid panels (including apoB when available), liver enzymes, CK, and fasting glucose, particularly when using RYR and berberine.
References
All references verified via PubMed, peer-reviewed journals, or clinicaltrials.gov as of April 2026.
1. Osadnik T, et al. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res. 2022;183:106402. PMID: 35988871.
2. Karageorgou D, et al. Safety and efficacy of red yeast rice extract for the reduction of hypercholesterolemia: a systematic review and meta-analysis. Nutrients. 2024;16(10):1453. PMID: 38794686.
3. Zhang K, et al. Red yeast rice for hyperlipidemia: a meta-analysis of 15 high-quality randomized controlled trials. Front Pharmacol. 2021;12:819482. PMID: 35111069.
4. Cicero AFG, et al. Red yeast rice for hypercholesterolemia: JACC Focus Seminar. J Am Coll Cardiol. 2021;77(5):620–628. PMID: 33538261.
5. Heber D, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69(2):231–236. PMID: 9989685.
6. Becker DJ, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830–839. PMID: 19528562.
7. Verhoeven V, et al. Red yeast rice lowers cholesterol in physicians – a double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2013;13:178. PMID: 23866314.
8. Blais JE, et al. Impact of berberine or berberine combination products on lipoprotein, triglyceride and biological safety marker concentrations: a systematic review and meta-analysis. Nutrients. 2023;15(9):2150. PMID: 37183391.
9. Li D, et al. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol. 2025;16:1572197.
10. Zamani M, et al. The effect of berberine supplementation on lipid profile and obesity indices: an umbrella review of meta-analyses. Complement Ther Med. 2023;79:102998.
11. Dong H, et al. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013;79(6):437–446. PMID: 23512497.
12. Lan J, et al. Efficacy and safety of berberine for dyslipidaemias: a systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25–36. PMID: 30466986.
13. Cicero AFG, et al. Metabolic and vascular effect of a new standardized bergamot phytocomplex: a three-arm, placebo controlled, double-blind clinical trial. Arch Med Sci. 2023;19(4):163368.
14. Ferro Y, et al. Citrus bergamia extract, a natural approach for cholesterol and lipid metabolism management: a randomized, double-blind placebo-controlled clinical trial. Foods. 2024;13(23):3883.
15. Mollace V, et al. Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers. Integr Food Nutr Metab. 2019;6(1). PMC: 6497409.
16. Law M. Plant sterol and stanol margarines and health. BMJ. 2000;320:861–864. Also: Katan MB, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78(8):965–978.
17. Ras RT, et al. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis. Br J Nutr. 2014;112(2):214–219. PMID: 24780090.
18. Han S, et al. Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis. Sci Rep. 2016;6:31337.
19. Noormohammadi M, et al. Effects of phytosterol supplementation on lipid profiles: a systematic review and meta-analysis. Medicine. 2024;103(42):e39994.
20. Gylling H, et al. Plant sterols and plant stanols in cholesterol management and cardiovascular prevention. Nutrients. 2023;15(13):2845.
21. Jovanovski E, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2018;108(5):922–932. PMID: 30239559.
22. Anderson JW, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr. 2000;71(2):472–479.
23. Ghavami A, et al. Soluble fiber supplementation and serum lipid profile: a systematic review and dose-response meta-analysis. Adv Nutr. 2023;14(3):465–474.
24. Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22.
25. Khan SU, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. eClinicalMedicine. 2021;38:100997.
26. Sahebkar A, et al. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018;58(15):2549–2556. PMID: 28609140.
27. Fatahi S, et al. Effects of artichoke leaf extract supplementation on lipid profile: a systematic review and dose-response meta-analysis. Phytother Res. 2022;36(1):267–281. PMID: 34569671.
28. Huang J, et al. Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc. 2011;111(11):1720–1729. PMID: 22027055.
29. Xu R, et al. Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr J. 2020;19:48. PMC: 7240975.
30. Ried K, et al. Effect of garlic on blood lipids: an updated meta-analysis. Nutr Rev. 2013;71(5):282–299. Also: Nutrients. 2025;17(16):2648 (functional foods review).
31. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.
32. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
33. D’Andrea E, et al. Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(4):e192224. PMC: 6481429.
34. Brown L, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30–42.
35. Musa-Veloso K, et al. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011;85(1):9–28. PMID: 21345662.
